Novavax News

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Jun 14 16:07 ET

Novavax | 8-K: Investor Presentation of Novavax, Inc.

Jun 6 07:01 ET

Novavax | DEFA14A: Others

Jun 5 06:06 ET

Novavax | 8-K: R&D President Filip Dubovsky Resigns

May 23 16:12 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 20 14:45 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 13 16:15 ET

Novavax | 8-K: Collaboration and License Agreement

May 13 14:44 ET

Novavax | 8-K: Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

May 10 08:09 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 8 16:57 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 7 17:26 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 6 16:45 ET

Novavax | DEFA14A: Others

Apr 29 08:03 ET

Novavax | DEF 14A: Definitive information statements

Apr 29 07:57 ET

Novavax | 8-K: Current report

Apr 26 16:39 ET

Novavax | 8-K: Confidential Settlement Agreements and Release Agreements

Mar 26 16:07 ET

Novavax | 8-K: Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Feb 28 08:12 ET

Novavax | 8-K: Entry into a Termination and Settlement Agreement

Feb 22 06:11 ET

Novavax | 8-K: Current report

Jan 31 08:01 ET

Novavax | 8-K: Results of Operations and Financial Condition

Jan 8 00:00 ET

Novavax | 8-K: Sothinathan Sinnathurai files alleged securities class action lawsuit against Novavax and certain members of the company's senior management

Dec 5, 2023 08:45 ET